Choose a Section
Most recent by E. Randy Craven, MD
SPONSORED CONTENT
July 04, 2020
2 min watch
Save
VIDEO: Surgeon shares his regimen implanting Durysta
SPONSORED CONTENT
May 19, 2020
2 min watch
Save
VIDEO: Bimatoprost SR implant shows sustained IOP lowering after three treatments

In this video perspective from the virtual American Society of Cataract and Refractive Surgery meeting, E. Randy Craven, MD, discusses phase 3 data that showed a sustained IOP-lowering impact after three treatments with Durysta (bimatoprost implant, Allergan), regardless of the number of glaucoma medications patients were on before the treatment.
SPONSORED CONTENT
October 18, 2019
2 min watch
Save
VIDEO: Bimatoprost SR shows continued IOP lowering at 1 year
SPONSORED CONTENT
May 25, 2019
2 min watch
Save
VIDEO: Bimatoprost SR shows long-term IOP lowering
SPONSORED CONTENT
May 22, 2018
2 min watch
Save
VIDEO: As research goes on, MIGS offers more options
SPONSORED CONTENT
July 25, 2008
4 min read
Save
Current options in adjunctive therapy
The goal of glaucoma management is to lower intraocular pressure and hinder the progression of the disease. If monotherapy does not provide adequate IOP lowering, then ophthalmologists need to consider treating patients with a different medication or with additional medications to achieve lower IOP.